In 2015, a 3p microdeletion involving only SLC6A1 and SLC6A11 was described in a patient with Doose Syndrome, a developmental epileptic encephalopathy associated with intellectual disability and early-onset epilepsy with myoclonic atonic seizures (previously myoclonic atonic epilepsy). This evidence concerns the gene SLC6A1 and developmental and epileptic encephalopathy.